When are adverse events reported in clinical trials?

Adverse events in clinical trials are reported during the entire duration of the study to ensure continuous monitoring of the participant's health and safety throughout the trial process. This ongoing reporting is crucial because it allows researchers to identify any potential risks associated with the investigational drug or intervention as they arise. Immediate reporting can lead to timely interventions, modifications to the study protocol, or the implementation of additional safety measures to protect participants.

Furthermore, regulatory authorities require continuous adverse event reporting as part of their oversight to ensure the ethical conduct of clinical trials and the safety of participants involved in the research. This comprehensive approach helps to maintain the integrity of the data collected and provides valuable information for analyzing the risk-benefit profile of a drug or treatment being studied.